News und Analysen

A legal opinion on the other side of Planet Earth put some juice into Illumina's (NASDAQ: ILMN) stock on Thursday. The gene-sequencing specialist saw its share price rise by over 3%, against the S&P

Investors are enjoying the ongoing bull run. The S&P 500 and Nasdaq Composite recently hit all-time highs. Though that's pretty exciting, bull markets don't last forever. Equities that can perform

If a dividend stock is struggling and falling in value, that pushes its yield up. This happens because while you are getting the same dividend, it is now costing you less money to acquire it. As

Biotech giant Amgen (NASDAQ: AMGN) isn't starting the year on a strong note. The company's shares are down by 5% since Jan. 1. It has dealt with some issues lately, especially subpar financial

Pfizer (NYSE: PFE) has seen its better days. Shares of the big drugmaker have plunged more than 50% from the highs set in late 2021. The pharma stock is down more than 30% over the last 12 months

There are many ways to spend $1,000. One could buy a brand-new flat-screen television, play the lottery, or keep it in a savings account. For people trying to increase their capital, though

Investors can be procrastinators. It's easy to get caught up in analyzing stocks so much that people put off buying them. But that doesn't have to be the case.

Three Motley Fool contributors have

Finding high-yielding companies isn't everything when investing in dividend stocks. Sometimes, companies' yields increase after their share prices drop significantly, which can occasionally be a

The stock market is at record levels these days, but one company that isn't reflecting that optimism is Pfizer (NYSE: PFE). Shares of the pharma giant are down 28% over the past 12 months as

Two companies stand at the center of the obesity drug market right now. Novo Nordisk continues to rake in money from its weight-loss drug Wegovy (and from off-label usage of its type 2 diabetes drug

Viatris (NASDAQ: VTRS) is a large and diverse pharmaceutical business that spun off from Pfizer in 2020. The company's medications are in 165 countries and much of its business centers around

Dividend stocks are great for several reasons. Some use the regular payouts they offer to complement their income, whether in retirement or otherwise, while others reinvest the money to boost

Pharmaceutical companies play a tremendous role in modern healthcare. While sometimes controversial, drugmakers design medicine to treat some of the worst ailments plaguing society and constantly

Stocks across a range of industries and sectors have dealt with unique challenges over the last few years. While some companies are still dealing with the effects of a slowdown in growth following

Stocks have been off to a very bullish start in 2024, and investors seem increasingly optimistic about the overall state of the market and the global economy. Now, that's not to say there aren't

Could this be the year biotech stocks bounce back? The industry has been in a slump over the past couple of years, but it started 2024 with a bang. The SPDR S&P Biotech ETF, which tracks an industry

Shares of Victoria's Secret (NYSE: VSCO) plummeted 29.7% on Thursday after the lingerie, clothing, and beauty-products retailer announced reasonably solid quarterly results but followed with

Per Cantor Fitzgerald analyst Louise Chen's calculations published March 4, Pfizer's (NYSE: PFE) stock is going to climb by around 75% to reach or surpass $45 over the coming quarters. Chen's

It's not always a good idea to chase trends in a bull market, but sometimes the new wave of promising companies is more than a fad. In the biotech and pharma industries, right now is an exciting

Rising tides don't always lift all boats. The S&P 500 index reached new all-time highs several times since 2024 began, but many of its components have not participated in the rally.

With most

Keep winners, ditch losers. That's usually not bad advice for investors. There's one big problem, though: Sometimes long-term winners temporarily look like losers.

Even the biggest and the best

Anti-obesity drugs rose in popularity last year, helping the leaders in this market -- notably Eli Lilly and Novo Nordisk -- crush the market. However, some medical device specialists got the wrong

Given its key role in the fight against COVID-19, the fact that Pfizer (NYSE: PFE) shares are down 56% from their 2021 peak isn't entirely surprising. Demand for its COVID-19 vaccine (Comirnaty) and

On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (NASDAQ: BIIB) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311